Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varenicline Versus Cytisine for Smoking Cessation in Primary Care
2019-003720-20Phase 4Completed
- Sponsor
- University of Zagreb School of Medicine
- Start
- Oct 2019
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of varenicline and cytisinicline in nicotine dependence (2 arms), sponsored by University of Zagreb School of Medicine. Primary endpoint: Seven-day point prevalence abstinence at 12 weeks. Started Oct 2019; status: completed.
02
Drugs
vareniclinecytisinicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on 2019-003720-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003720-20.